Alimera (ALIM), pSivida (PSDV) Move Higher as Journal Questions Lucentis Effectiveness
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/21/2026
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Walmart shares fall despite earnings beat
- Alibaba stock dips as Q2 profit misses estimates despite strong AI cloud growth
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Moderna stock pulls back after massive one-day rally: analysts weigh in
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Supermicro probe finds no senior management link to export violations
- SpaceX shares fall as second lockup period ends
- Hertz Global amends voting agreement with CK Amarillo after lawsuit
Alimera (ALIM) Receives CRL for ILUVIEN, FDA Rejects NDA Due to Insufficient Safety
November 11, 2011 12:09 PM ESTAlimera Sciences, Inc., (Nasdaq: ALIM) today announced that it has received a complete response letter from the U.S. FDA in response to the New Drug Application for ILUVIEN for the treatment of diabetic macular edema associated with diabetic retinopathy.
The FDA stated that it was unable to approve the ILUVIEN New Drug Application because the New Drug Application did... More
